Brief: Bergenbio Says Effect Of Bemcentinib Demonstrated Potent Antiviral Effects In Preclinical SARS-CoV-2 And Other Coronavirus Models

Oncoinvent ASA

06/03/2021 10:18

March 6 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * BERGENBIO PRESENTS PRECLINICAL COVID-19 DATA AT ANNUAL
CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI
2021)
    * BEMCENTINIB REPORTED TO REDUCE VIRUS INTERNALIZATION,
WITHOUT
AFFECTING VIRUS BINDING, BY LIMITING ENDOSOMAL ENTRY ROUTE TO
HOST CELLS
    * EFFECT OF BEMCENTINIB DEMONSTRATED POTENT ANTIVIRAL
EFFECTS IN
PRECLINICAL SARS-COV-2 AND OTHER CORONAVIRUS MODELS
    * CO'S ONGOING PHASE II TRIAL EVALUATING BEMCENTINIB FOR
TREATMENT
OF HOSPITALISED COVID-19 PATIENTS IN SOUTH AFRICA AND INDIA

Source text for Eikon:  ID:nWkr6JB8Dv 
Further company coverage:  BGBIO.OL 

 ((Reuters.Briefs@thomsonreuters.com;))